drugset / Trial / NCT06346184

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers

NCT06346184

Phase 1 Completed 37 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HCP2303 and co-administration of each component in fasting condition in healthy volunteers.

Timeline

Start
2024-05-02
Primary completion
2024-06-10
Completion
2024-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject HCP2303 Unknown
Subject RLD2102 Unknown
Subject RLD2302 Unknown

Indications

No indication recorded.